Article: ImClone, Bristol Settle Feud

00-00-0000
ImClone Systems Inc. on Tuesday settled its public feud with Bristol- Myers Squibb Co. over the handling of a $2 billion deal to co-market a highly touted experimental cancer drug.

ImClone agreed to accept less money and revise its profit-sharing agreement with the drug titan, which was also given management of a key committee assigned to shepherd the drug Erbitux through the regulatory process.

ImClone agreed to accept $100 million less than the $800 million the drug titan owed the small New York-based biotechnology company to share Erbitux's future profits once approved by the Food and Drug Administration.

Bristol, also based in New York, agreed in September to pay ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!